SLC7A5: A Protein Involved in The Transport of Cationic Amino Acids and Potential Drug Target

Target Name: SLC7A5

NCBI ID: G8140

SLC7A5

SLC7A5: A Protein Involved in The Transport of Cationic Amino Acids and Potential Drug Target

SLC7A5, also known as cationic amino acid transporter, y+ system member 5, is a protein that is expressed in various tissues and organs throughout the body. It plays a crucial role in the transport of cationic amino acids, which are essential nutrients that are essential for the proper functioning of many cellular processes. SLC7A5 is also known as a drug target and has been identified as a potential biomarker for several diseases.

SLC7A5 is a member of the solute carrier family 7, which is a large family of transporters that play a vital role in the transport of various types of molecules throughout the body. These transporters are responsible for ensuring that substances are transported to their proper destinations and for maintaining the homeostasis of the body. SLC7A5 is a cationic amino acid transporter, which means that it is responsible for the transport of cationic amino acids across the cell membrane.

The proper functioning of cationic amino acids is essential for the development and maintenance of healthy cellular processes. Many cellular processes require the presence of cationic amino acids, such as glutamate, which is a neurotransmitter that is involved in many important cellular processes. SLC7A5 is also involved in the transport of other types of cationic amino acids, such as aspartate and lysine, which are also essential nutrients.

SLC7A5 is also known as a drug target because it has been identified as a potential target for several drugs that are used to treat various diseases. For example, SLC7A5 has been targeted by drugs that are used to treat hypertension, heart failure, and cancer. These drugs work by inhibiting the function of SLC7A5, which would reduce its ability to transport cationic amino acids across the cell membrane and potentially lead to the disruption of cellular processes that are necessary for the health and survival of the cell.

In addition to its potential as a drug target, SLC7A5 has also been identified as a potential biomarker for several diseases. For example, studies have shown that changes in the expression of SLC7A5 can be an indication of certain diseases, such as heart failure and cancer. Additionally, SLC7A5 has been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of healthy tissues. For example, SLC7A5 has been shown to be involved in the regulation of cell division and in the maintenance of the cytoskeleton.

SLC7A5 is also known as a protein that is expressed in many different tissues and organs throughout the body. It is found in the brain, heart, liver, and kidneys, among other tissues. This means that it is a potential biomarker that can be used to diagnose and monitor a variety of diseases. For example, changes in the expression of SLC7A5 have been shown to be an indication of certain diseases, such as heart failure and cancer.

In conclusion, SLC7A5 is a protein that plays a crucial role in the transport of cationic amino acids across the cell membrane. It is also known as a drug target and has been identified as a potential biomarker for several diseases. Further research is needed to fully understand the role of SLC7A5 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 7 Member 5

Functions: The heterodimer with SLC3A2 functions as sodium-independent, high-affinity transporter that mediates uptake of large neutral amino acids such as phenylalanine, tyrosine, leucine, histidine, methionine, tryptophan, valine, isoleucine and alanine (PubMed:9751058, PubMed:10049700, PubMed:11557028, PubMed:10574970, PubMed:11564694, PubMed:12117417, PubMed:12225859, PubMed:25998567, PubMed:30867591, PubMed:18262359, PubMed:15769744). The heterodimer with SLC3A2 mediates the uptake of L-DOPA (By similarity). Functions as an amino acid exchanger (PubMed:11557028, PubMed:12117417, PubMed:12225859, PubMed:30867591). May play a role in the transport of L-DOPA across the blood-brain barrier (By similarity). May act as the major transporter of tyrosine in fibroblasts (Probable). May mediate blood-to-retina L-leucine transport across the inner blood-retinal barrier (By similarity).Can mediate the transport of thyroid hormones diiodothyronine (T2), triiodothyronine (T3) and thyroxine (T4) across the cell membrane (PubMed:11564694). When associated with LAPTM4B, the heterodimer formed by SLC3A2 and SLC7A5 is recruited to lysosomes to promote leucine uptake into these organelles, and thereby mediates mTORC1 activation (PubMed:25998567). Involved in the uptake of toxic methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes (PubMed:12117417). Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the membrane (PubMed:15769744)

The "SLC7A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC7A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets